Vivace Therapeutics
PrivateLast Round
Series D
Mar 12, 2025
Est. Valuation
$125M
Total Funding Raised
$105M
Company Overview
Vivace Therapeutics operates in Healthcare & Life Sciences and is based in San Mateo, California. Its latest recorded funding round was a Series D round in March 2025.
Vivace Therapeutics is a biotechnology company that develops small molecule cancer therapies targeting the Hippo-YAP signaling pathway.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivace Therapeutics Comparables
Compare Vivace Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ikena Oncology | 83% | |
| Insilico Medicine | 82% | |
| XtalPi | 77% |
For institutional investors. Book with your work email.
Vivace Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Mar 12, 2025 | ||||
| Series C | Dec 16, 2020 | ||||
| Series B | Jun 28, 2017 | ||||
| Series A | Jan 20, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vivace Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series C, Series D |
| Boxer Capital | Series C |
| BioInnovation Capital | Series B |
| WuXi Healthcare Ventures | Series B, Series A |
| Sequoia Capital | Series C |
| Cenova Capital | Series C, Series D, Series B |
| Canaan Partners | Series C, Series B, Series D, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 49% MoM.
- Mar 12, 2025
$35M round completed.
For institutional investors. Book with your work email.
Vivace Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vivace Therapeutics's valuation, stock price, and market status.
Is Vivace Therapeutics a public or private company?
Vivace Therapeutics is a private company.
What is the current stock price of Vivace Therapeutics?
Vivace Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vivace Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vivace Therapeutics worth (valuation)?
Vivace Therapeutics's valuation is estimated at $125.0M based on funding round data.
Can I buy Vivace Therapeutics stock?
Vivace Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vivace Therapeutics's last funding round?
Vivace Therapeutics's most recent funding round was Series D on March 12, 2025.
Who are the main investors in Vivace Therapeutics?
Key investors in Vivace Therapeutics include RA Capital Management, Boxer Capital, WuXi Healthcare Ventures, Cenova Capital, Canaan Partners.
Will Vivace Therapeutics IPO soon?
No public IPO plans have been announced for Vivace Therapeutics.
How can I track Vivace Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vivace Therapeutics's shares on secondary markets.